Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene
By, Admin1 min read
Share
Prelude Therapeutics Incorporated announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
